Literature DB >> 30144554

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.

Zobair Younossi1, Maria Stepanova2, Arun J Sanyal3, Stephen A Harrison4, Vlad Ratziu5, Manal F Abdelmalek6, Anna Mae Diehl6, Stephen Caldwell7, Mitchell L Shiffman8, Raul Aguilar Schall9, Bryan McColgan9, G Mani Subramanian9, Robert P Myers9, Andrew Muir6, Nezam H Afdhal10, Jaime Bosch11, Zachary Goodman2.   

Abstract

BACKGROUND & AIMS: Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis and NASH-related cirrhosis from a cohort with longitudinal follow-up data.
METHODS: Patients with cryptogenic cirrhosis or NASH cirrhosis were screened for a clinical trial. Patients with <5% hepatic steatosis regardless of other histologic features were considered to have cryptogenic cirrhosis. Clinico-laboratory data and adjudicated liver-related events (e.g. decompensation, qualification for transplantation, death) were available.
RESULTS: A total of 247 patients with cirrhosis (55.3 ± 7.4 years, 37% male) were included; 144 had NASH cirrhosis and 103 had cryptogenic cirrhosis. During a median follow-up of 29 (IQR 21-33) months (max 45 months), 20.6% of patients had liver-related clinical events. Patients with NASH cirrhosis and cryptogenic cirrhosis were of a similar age and gender, as well as having a similar body mass index, PNPLA3 rs738409 genotype, and prevalence of diabetes (p >0.05). However, patients with cryptogenic cirrhosis had higher serum fibrosis markers and greater collagen content and α-smooth muscle actin expression on liver biopsy. Compared to cirrhotic patients with NASH, patients with cryptogenic cirrhosis experienced significantly shorter mean time to liver-related clinical events (12.0 vs. 19.4 months; p = 0.001) with a hazard ratio of 1.76 (95% CI 1.02-3.06).
CONCLUSIONS: Populations with NASH and cryptogenic cirrhosis have similar demographics, but patients with cryptogenic cirrhosis have evidence of more active fibrosis and a higher risk of liver-related clinical events. Thus, we believe these patients belong to the same spectrum of disease, with cryptogenic cirrhosis representing a more advanced stage of fibrosis. LAY
SUMMARY: Significant liver damage and cirrhosis of the liver may develop without a known cause - a liver disease referred to as cryptogenic cirrhosis. In this work we found that, in the presence of metabolic abnormalities, cryptogenic cirrhosis may actually be a part of the non-alcoholic fatty liver disease spectrum. Yet, it appears to be more progressive than typical non-alcoholic fatty liver disease, leading to advanced liver disease at a faster rate.
Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cryptogenic cirrhosis; Fatty liver; NAFLD; NASH; Outcomes

Year:  2018        PMID: 30144554     DOI: 10.1016/j.jhep.2018.08.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Authors:  Pegah Golabi; Logan Rhea; Linda Henry; Zobair M Younossi
Journal:  Hepatol Int       Date:  2019-11-07       Impact factor: 6.047

Review 2.  Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges.

Authors:  Muhammad Imran Ahmad; Muhammad Umair Khan; Sudha Kodali; Akshay Shetty; S Michelle Bell; David Victor
Journal:  J Hepatocell Carcinoma       Date:  2022-06-01

3.  Inhibitory Effects of Mongolian Medicine Yihe-Tang on Continuous Darkness Induced Liver Steatosis in Zebrafish.

Authors:  Rigaiqiqige Sa; Chi Feng; Hongxia Bai; Xiaoyu Yin; Lei Song; Xiaodong Hu; Rui Xu; Xinshan Li; Wu Dong; Jingfeng Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-20       Impact factor: 2.650

Review 4.  Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression.

Authors:  Krishna Chaitanya Thandra; Adam Barsouk; Kalyan Saginala; John Sukumar Aluru; Prashanth Rawla; Alexander Barsouk
Journal:  Clin Exp Hepatol       Date:  2020-12-30

5.  Survival after first diagnosis of oesophageal or gastric varices in a single centre in northern Sweden: a retrospective study.

Authors:  Richard Thörn; Evelina Christensen; Jonas Wixner; Pontus Karling; Mårten Werner
Journal:  Clin Exp Hepatol       Date:  2022-03-28

6.  Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Gian Paolo Caviglia; Angelo Armandi; Chiara Rosso; Silvia Gaia; Serena Aneli; Emanuela Rolle; Maria Lorena Abate; Antonella Olivero; Aurora Nicolosi; Marta Guariglia; Davide Giuseppe Ribaldone; Patrizia Carucci; Giorgio Maria Saracco; Elisabetta Bugianesi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

7.  Hospitalisation for cirrhosis in Australia: disparities in presentation and outcomes for Indigenous Australians.

Authors:  Patricia C Valery; Paul J Clark; Gregory Pratt; Christina M Bernardes; Gunter Hartel; Maree Toombs; Katharine M Irvine; Elizabeth E Powell
Journal:  Int J Equity Health       Date:  2020-02-17

8.  Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis.

Authors:  Sang Bong Ahn; Elizabeth E Powell; Anthony Russell; Gunter Hartel; Katharine M Irvine; Chris Moser; Patricia C Valery
Journal:  Hepatol Commun       Date:  2020-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.